Randomised controlled trial of daily versus stoss vitamin <scp>D</scp> therapy in <scp>A</scp>boriginal children

Tan, Jason; Kearns, Paula; Martin, Andrew C.; Siafarikas, Aris

doi:10.1111/jpc.12781

Cited by 15 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High-dose oral vitamin D has been shown to be safe and effective at rapidly increasing serum 25-OHD levels in vitamin D deficiency (23,30,31). Stoss therapy has been used successfully in children with cystic fibrosis (25), chronic kidney disease (26) and prior to hematopoietic stem cell transplant (27).…”

Section: Discussionmentioning

confidence: 99%

Single high-dose oral vitamin D3 treatment in New Zealand children with inflammatory bowel disease

Martin¹,

Rigterink²,

Adamji³

et al. 2019

Transl Pediatr

View full text Add to dashboard Cite

Background: High-dose oral vitamin D (stoss) is a novel treatment in children with inflammatory bowel disease (IBD). Vitamin D supplementation may have benefits in IBD beyond bone health including reduced disease activity and improvements in inflammatory markers. The aim of this study was to retrospectively assess the efficacy, safety and impact on disease activity of single oral high-dose vitamin D3 therapy in New Zealand (NZ) children with IBD and vitamin D deficiency. Methods: In this retrospective chart review, children with IBD and vitamin D deficiency [serum 25-OH vitamin D level (25-OHD) <50 nmol/L] in Christchurch, NZ, who were managed with single highdose vitamin D3 therapy were identified. Measurements of serum 25-OHD, calcium and standard serum inflammatory markers prior to and up to 6 months following stoss therapy were extracted from patient records. Disease activity was also defined using the Pediatric Crohn's Disease (CD) Activity Index (PCDAI) at time points before and 3 months following stoss. Results: Twenty-eight doses of stoss were given to 23 children, aged 3-16 years. Mean 25-OHD levels

show abstract

Section: Discussionmentioning

confidence: 99%

Single high-dose oral vitamin D3 treatment in New Zealand children with inflammatory bowel disease

Martin¹,

Rigterink²,

Adamji³

et al. 2019

Transl Pediatr

View full text Add to dashboard Cite

show abstract

“…The majority of the trials in children have used single high doses of vitamin D [ 35 , 36 , 37 , 38 , 39 , 40 ] or compared different doses or duration of depot preparations [ 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ] for treatment. There are only limited numbers of trials comparing low dose daily against intermittent depot vitamin D therapy [ 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 ]. Studies using depot vitamin D treatment in children suggest that high-dose repletion approaches are safe and effective.…”

Section: Discussionmentioning

confidence: 99%

Randomised Controlled Trial Comparing Daily Versus Depot Vitamin D3 Therapy in 0–16-Year-Old Newly Settled Refugees in Western Australia Over a Period of 40 Weeks

et al. 2018

Self Cite

View full text Add to dashboard Cite

Vitamin D deficiency is highly prevalent in newly settled refugees in Western Australia (WA). If adherence to daily vitamin D therapy is problematic, depot therapy is a therapeutic alternative. The aim of this study was to compare daily versus depot treatment and factors influencing the therapeutic outcome. Newly settled refugees (n = 151) with 25(OH)D levels less than 78 nmol/L were randomised to receive daily or depot vitamin D therapy with eight weekly interval follow up to 40 weeks. Biochemical and clinical parameters were collected at each visit. Generalized Linear Mixed Models (GLMM) examined the longitudinal changes over time controlling for confounders including age, gender, treatment arm, season, country of refuge/origin and sun exposure score. Participants were aged 5.5 months to 16.0 years (75 males, 83 females). Both treatment groups achieved vitamin D sufficiency. The daily treatment group had significantly higher 25(OH)D levels at each visit post baseline and a higher proportion of participants with levels above 50 nmol/L at all time points. Time, treatment group, calcium and sun exposure score were significant predictors of 25(OH)D serum levels. Depot vitamin D therapy is an alternative to daily treatment in this at-risk group of children and adolescents in whom treatment adherence is problematic.

show abstract

“…Participants were treated with a single dose of cholecalciferol, according to hospital guidelines. Studies comparing single one-off with maintenance vitamin D therapy have shown it to be safe and effective ( 30 , 31 ), even up to 12 months after administration ( 32 ). However, randomised controlled trials provide some evidence to support the value of vitamin D maintenance therapy, rather than single doses, in paediatric asthma patients to prevent exacerbations ( 33 ).…”

Section: Discussionmentioning

confidence: 99%

A pilot interventional study to evaluate the impact of cholecalciferol treatment on HbA1c in type 1 diabetes (T1D)

Perchard

Magee

Whatmore

et al. 2017

Endocrine Connections

View full text Add to dashboard Cite

BackgroundHigher 25(OH)D3 levels are associated with lower HbA1c, but there are limited UK interventional trials assessing the effect of cholecalciferol on HbA1c.Aims(1) To assess the baseline 25(OH)D3 status in a Manchester cohort of children with type 1 diabetes (T1D). (2) To determine the effect of cholecalciferol administration on HbA1c.MethodsChildren with T1D attending routine clinic appointments over three months in late winter/early spring had blood samples taken with consent. Participants with a 25(OH)D3 level <50 nmol/L were treated with a one-off cholecalciferol dose of 100,000 (2–10 years) or 160,000 (>10 years) units. HbA1c levels before and after treatment were recorded.ResultsVitamin D levels were obtained from 51 children. 35 were Caucasian, 11 South Asian and 5 from other ethnic groups. 42 were vitamin D deficient, but 2 were excluded from the analysis. All South Asian children were vitamin D deficient, with mean 25(OH)D3 of 28 nmol/L. In Caucasians, there was a negative relationship between baseline 25(OH)D3 level and HbA1c (r = −0.484, P < 0.01). In treated participants, there was no significant difference in mean HbA1c at 3 months (t = 1.010, P = 0.328) or at 1 year (t = −1.173, P = 0.248) before and after treatment. One-way ANCOVA, controlling for age, gender, ethnicity, BMI and diabetes duration showed no difference in Δ HbA1c level.ConclusionWe report important findings at baseline, but in children treated with a stat dose of cholecalciferol, there was no effect on HbA1c. Further studies with larger sample sizes and using maintenance therapy are required.

show abstract

Randomised controlled trial of daily versus stoss vitamin D therapy in Aboriginal children

Abstract: Vitamin D insufficiency is common in Aboriginal children of Western Australia and stoss therapy is a safe alternative to daily vitamin D therapy but requires further evaluation of timing and doses.

Cited by 15 publications

References 35 publications

Single high-dose oral vitamin D3 treatment in New Zealand children with inflammatory bowel disease

Single high-dose oral vitamin D3 treatment in New Zealand children with inflammatory bowel disease

Randomised Controlled Trial Comparing Daily Versus Depot Vitamin D3 Therapy in 0–16-Year-Old Newly Settled Refugees in Western Australia Over a Period of 40 Weeks

A pilot interventional study to evaluate the impact of cholecalciferol treatment on HbA1c in type 1 diabetes (T1D)

Contact Info

Product

Resources

About